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Influenza Positive Tests Reported to CDC by U.S. Public 
Health Laboratories, 2018-19 Season
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Characterization of U.S. Influenza A (H1N1)pdm09 and B 
Viruses Collected September 30, 2018 to May 18, 2019 
 All 1,251 influenza A (H1N1)pdm09 viruses tested belong to genetic group 6B.1A
–
–
–
–
96.1% were well inhibited by ferret antisera against A/Michigan/45/2015
 All 203 B/Yamagata lineage viruses belong to Y3 clade
100% were well inhibited by ferret antisera against B/Phuket/3073/2013
 3 genetically and antigenically distinct B/Victoria subclades cocirculated
V1A (14.7%), V1A.1 (50.4%), V1A-3Del (34.9%)
The 2018-19 Northern Hemisphere vaccines contained a B/Colorado/6/2017-
like V1A.1 virus
Characterization of U.S. Influenza A (H3N2) Viruses 
Collected September 30, 2018 to May 18, 2019 
 Phylogenetic analysis of the HA genes of H3N2 viruses 
show co-circulation of multiple clades/subclades 
 The proportion and geographic spread of viruses 
belonging to clade 3C.3a increased as the season 
progressed
 The 3C.3a viruses are antigenically distinguishable from 
the 3C.2a and 3C.2a1 viruses including the 
A/Singapore/INFIMH-16-0019/2016 (3C.2a1), a cell-
propagated reference virus representing the A(H3N2) 
component of 2018-19 Northern Hemisphere influenza 
vaccines.
 Circulation of antigenically drifted viruses can impact 
vaccine effectiveness
Changing Proportion of H3 Genetic Clades/Sub-clades
Vaccine Virus Selection for 2019-20
 WHO Consultation on the Composition of Influenza Virus Vaccines for Use 
in the 2019-2020 Northern Hemisphere Influenza Season - February 18 –
21
–
–
–
–
A/Brisbane/02/2018 (H1N1)pdm09-like virus
A(H3N2) virus to be announced on 21 March 2019
B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage)
B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage) –
quadrivalent only
 March 6, 2019: Vaccines and Related Biological Products Committee 
Meeting 
Vaccine Virus Selection for 2019-20
 WHO and FDA Vaccines and Related Biological Products Committee 
Recommended Composition of Influenza Virus Vaccines for Use in the 
2019-2020 Northern Hemisphere Influenza Season:
–
–
–
–
A/Brisbane/02/2018 (H1N1)pdm09-like virus
A/Kansas/14/2017 (H3N2)-like virus (3C.3a)
B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage)
B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage) –
quadrivalent only
Percentage of Outpatient Visits for Influenza-like 
Illness, 2018-19 and Selected Previous Seasons
Laboratory Confirmed Influenza-Associated Hospitalizations
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Influenza Severity Assessment by Age Group, 
2003-04 – 2018-19 Seasons
• Severity of the 2018-19 season 
classified as a moderate overall 
and in all age categories
• Information on how CDC 
classifies severity is available at 
https://www.cdc.gov/flu/about/
classifies-flu-severity.htm
Season Child Adults Older Adults All Ages
2018-–19 Moderate Moderate Moderate Moderate
2017–18 High High High High
2016-17 Moderate Moderate Moderate Moderate
2015–16 Low Moderate Low Moderate
2014–15 Moderate Moderate High High
2013–14 Moderate Moderate Moderate Moderate
2012–13 Moderate Moderate High Moderate
2011–12 Low Low Low Low
2010–11 Moderate Moderate Moderate Moderate
2009–10 Very High Moderate Low Moderate
2008–09 Low Low Low Low
2007–08 Moderate Moderate Moderate Moderate
2006–07 Low Low Low Low
2005–06 Low Low Low Low
2004–05 Low Moderate Moderate Moderate
2003–04 Very High Moderate High High
2018-19 Flu Season: Preliminary Burden Estimates
https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm
Influenza Activity in Australia
• Australia’s influenza season began 
earlier than typical this year
• Number of reported influenza 
positives similar to 2017
• Currently influenza A(H3N2) 
predominant 
• Multiple clades detected
– 3C.2a1b, not 3C.3a, is the 
predominant clade
Summary
 The severity of the 2018-19 influenza season was classified as moderate
 The season was notable for 2 waves of influenza A viruses of similar 
magnitude, an influenza A(H1N1)pdm09 wave and an H3N2 wave
 The majority of H3N2 viruses belonged to the 3C.3a genetic group which is 
antigenically distinct from the 3C.2a genetic group
 The recommended H3N2 component for the 2019-20 Northern 
Hemisphere vaccine is an A/Kansas/14/2017-like virus, which belongs to 
genetic group 3C.3a 
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
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